Today, seven founding member organizations from the private, public, and not-for-profit sectors announced the establishment of the Inclusive Life Sciences Collaboration (Collaboration). The Collaboration aims to create a community of like-minded individuals and organizations committed to creating inclusive organizational cultures across the life sciences sector.
Read MoreBELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced positive findings from a preplanned administrative interim analysis of the ongoing Phase 2b SOOTHE trial of BLU-5937, the Company’s highly selective P2X3 antagonist, in patients with refractory chronic cough (“RCC”).
Read MoreThe continuing development of Shigamab™ has been guaranteed. This transaction allows BELLUS Health to maintain financing for its activities until the end of 2018.
Read More
